AbbVie (ABBV) has successfully concluded its acquisition of Cerevel Therapeutics, integrating the latter into its operations. This acquisition is projected to enhance adjusted earnings per share starting in 2030.
The company has reiterated its 2024 full-year adjusted EPS guidance, maintaining the range of $10.71 to $10.91. This forecast accounts for a dilution impact of $0.19 per share stemming from the completed acquisition of Cerevel. Additionally, the 2024 guidance considers an adverse impact of $0.60 per share due to acquired in-process research and development (IPR&D) and milestone expenses incurred up to the second quarter of the current year.
AbbVie has also confirmed its third-quarter adjusted EPS guidance, projecting a range of $2.92 to $2.96.
